Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies

Lung, Respiratory and Thoracic Cancer

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Lung Cancer

Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL

doi: 10.1016/j.lungcan.2026.109385

Lung, Respiratory and Thoracic Cancer

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study

Eur J Cancer

Alexander M, Cheng Y, Lee SH, Passaro A, Spira AI, Cho BC, Lim SM, Ohe Y, Nagrial A, Tan JL, Wainsztein V, Ramos E, Campelo MDRG, Akamatsu H, Nguyen D, Cortot AB, Zer A, Erdem D, Sanborn RE, Emde TO, Minchom AR, Zurawski B, Ferreira ML, Yang JC, Marmarelis ME, Schuchard J, Alves J, Ghosh D, Balaburski G, Verheijen RB, Ribeiro L, Gamil M, Bauml JM, Baig M, Leighl NB

doi: 10.1016/j.ejca.2025.115624

Lung, Respiratory and Thoracic Cancer

Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

J Thorac Oncol

Zhu H, Al Saifi S, Bahig H, Cooper A, Abrão FC, Corrales L, Faivre-Finn C, Filippi AR, Fitzgerald B, Khosla D, Lam VK, Le X, Menezes V, Newsom-Davis T, Qin A, Putora PM, Munoz-Schuffenegger P, Siva S, Yu NY, Louie AV

doi: 10.1016/j.jtho.2025.11.006

Lung, Respiratory and Thoracic Cancer

Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer

Eur J Cancer

Lavigne D, Le Péchoux C, Botticella A, Planchard D, Besse B, Lavaud P, Gazzah A, Jouveshomme S, Guezour N, Naltet C, Pradère P, Remon J, Levy A

doi: 10.1016/j.ejca.2026.116881

Lung, Respiratory and Thoracic Cancer

European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy

Lung Cancer

Lula LJ, Costa R, Huang L, Rushwan A, Domjan M, Franssen AJPM, Weedle R, Trabalza Marinucci B, Barreda CF, Jasovic C, Whooley J, Matache RS, Özgür EG, Ryan R, Young V, Tahiri M, Fernandes P, Rendina EA, Bekiroglu N, de Loos ER, Jimenez M, Savu C, Bolca C, Stupnik T, Fitzmaurice GJ, D'Andrilli A, Brunelli A, Petersen RH

doi: 10.1016/j.lungcan.2026.109410

Lung, Respiratory and Thoracic Cancer

Safety and outcomes of intensity modulated proton therapy in patients with non small cell lung cancer with interstitial lung disease

Lung Cancer

Roden RT, Harmsen WS, Breen WG, Moffett JN, Pulsipher SD, Olivier KR, Garces YI, Park SS, Merrell KW, Sarkaria JN, Owen D

doi: 10.1016/j.lungcan.2025.108789

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

Lung, Respiratory and Thoracic Cancer

Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial

J Thorac Oncol

Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, Poté N, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Favier L, Martinez S, Mascaux C, Odier L, Cortot A, Audigier-Valette C, Langlais A, Amour E, Morin F, Antoine M, Gounant V, Westeel V, Toffart AC

doi: 10.1016/j.jtho.2026.103609

Lung, Respiratory and Thoracic Cancer

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

ESMO Open

Frehner L, Schär S, Hayoz S, Guckenberger M, Finazzi T, Mark M, Addeo A, Mauti LA, Betticher D, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D, Opitz I, Ris HB, Özdemir BC, Schmid S

doi: 10.1016/j.esmoop.2025.105870

Related content

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study

Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer

European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy

Safety and outcomes of intensity modulated proton therapy in patients with non small cell lung cancer with interstitial lung disease

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14